Medicare AdvantagePrior AuthMedium impact
Taltz (ixekizumab) (New)
Humana·Dermatology, Rheumatology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has introduced a new prior authorization policy for Taltz (ixekizumab) effective January 1, 2026. The policy covers four conditions (psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis) and requires patients to have tried and failed two specific medications before Taltz can be approved.
Action Required
By January 1, 2026: Billing team must implement prior authorization requirements for all Taltz (ixekizumab) prescriptions for Humana Medicare Advantage patients. Providers must document patient diagnosis, age requirements (18+ for most conditions, 6+ for plaque psoriasis), and prior therapy failures with two specified medications before submitting prior auth requests. Update EMR templates to capture required criteria documentation. Claims will be denied without proper prior authorization.